Harmony P Garges
Overview
Explore the profile of Harmony P Garges including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
216
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tan D, Antinori A, Eu B, Galindo Puerto M, Kinder C, Sweet D, et al.
J Acquir Immune Defic Syndr
. 2024 Dec;
98(4):401-409.
PMID: 39676239
Background: Modest weight and lipid changes have been observed in cabotegravir plus rilpivirine long-acting (CAB + RPV LA) phase 3/3b studies. The SOLAR study included standardized evaluations of weight and...
2.
Johansen I, Roen A, Kraef C, Martin-Iguacel R, Nemeth J, Fenner L, et al.
Int J Infect Dis
. 2024 Aug;
147:107199.
PMID: 39142437
Objectives: Tuberculosis (TB) risk after initiation of antiretroviral treatment (ART) is not well described in a European setting, with an average TB incidence of 25/10 in the background population. Methods:...
3.
Gutner C, Hocqueloux L, Jonsson-Oldenbuttel C, Vandekerckhove L, van Welzen B, Slama L, et al.
J Int AIDS Soc
. 2024 Jul;
27(7):e26243.
PMID: 38978405
Introduction: Cabotegravir plus rilpivirine (CAB + RPV) is the first complete long-acting (LA) regimen recommended for maintaining HIV-1 virological suppression. Cabotegravir And Rilpivirine Implementation Study in European Locations (CARISEL) is...
4.
Ross L, Cotton M, Cassim H, Garges H, van Dijkman S, Morarji K, et al.
AIDS Res Hum Retroviruses
. 2024 Jul;
40(10):606-613.
PMID: 38973446
APV20002 was a multicenter, international, open-label study that began in 2003 investigating the pharmacokinetics, efficacy, and safety of ritonavir-boosted fosamprenavir (FPV/r) oral solution (OS) in combination with nucleoside reverse transcriptase...
5.
Chammartin F, Mocroft A, Egle A, Zangerle R, Smith C, Mussini C, et al.
Clin Infect Dis
. 2023 Dec;
78(4):995-1004.
PMID: 38092042
Background: Human immunodeficiency virus (HIV) infection leads to chronic immune activation/inflammation that can persist in virally suppressed persons on fully active antiretroviral therapy (ART) and increase risk of malignancies. The...
6.
Ramgopal M, Castagna A, Cazanave C, Diaz-Brito V, Dretler R, Oka S, et al.
Lancet HIV
. 2023 Aug;
10(9):e566-e577.
PMID: 37567205
Background: Cabotegravir plus rilpivirine is the only approved complete long-acting regimen for the maintenance of HIV-1 virological suppression dosed every 2 months. The SOLAR study aimed to compare long-acting cabotegravir...
7.
Orkin C, Schapiro J, Perno C, Kuritzkes D, Patel P, DeMoor R, et al.
Clin Infect Dis
. 2023 Jun;
77(10):1423-1431.
PMID: 37340869
Background: Previously reported post hoc multivariable analyses exploring predictors of confirmed virologic failure (CVF) with cabotegravir + rilpivirine long-acting (CAB + RPV LA) were expanded to include data beyond week...
8.
Andriole G, Bostwick D, Gomella L, Marberger M, Montorsi F, Tammela T, et al.
Urology
. 2014 Jun;
84(2):393-9.
PMID: 24916669
Objective: To explore explanations for the numerical imbalance of biopsy-detected Gleason 8-10 prostate cancers (PCa) diagnosed in years 3-4 in the dutasteride and placebo groups of the Reduction by Dutasteride...
9.
Fortuny C, Duiculescu D, Cheng K, Garges H, Cotton M, Tamarirt D, et al.
Pediatr Infect Dis J
. 2013 Jul;
33(1):50-6.
PMID: 23811744
Background: Pharmacokinetics, safety and antiviral activity of twice-daily fosamprenavir with or without ritonavir were evaluated in 2- to 18-year-old protease inhibitor-naïve and -experienced HIV-1-infected children. Methods: Serial pharmacokinetic samples were...
10.
Cotton M, Cassim H, Pavia-Ruz N, Garges H, Perger T, Ford S, et al.
Pediatr Infect Dis J
. 2013 Jul;
33(1):57-62.
PMID: 23811743
Background: Pharmacokinetics, safety and antiviral activity of fosamprenavir (FPV) with ritonavir (RTV) twice daily were evaluated in HIV-1-infected infants and children 4 weeks to <2 years over 48 weeks. Methods:...